First Page | Meta Content | |
---|---|---|
![]() | Document Date: 2013-01-28 18:35:47Open Document File Size: 116,01 KBShare Result on FacebookCompanySavient Pharmaceuticals Inc. / /EventFDA Phase / /IndustryTermcolorless solution / healthcare settings / healthcare providers / mg/mL solution / healthcare setting / /MedicalConditionarrhythmia / Congestive Heart Failure / hypertension / Congestive Heart Failure KRYSTEXXA / chest pain / disease / insulin dependent diabetes mellitus / nasopharyngitis / dyspnea / Carcinogenesis / cardiac failure/left ventricular dysfunction / dyslipidemia / nausea / Gout Flares Gout / ANAPHYLAXIS / diabetes / erythema / G6PD deficiency / delayed-type hypersensitivity / type hypersensitivity / vomiting / gout / chronic kidney disease / urticaria / chronic gout / coronary artery disease / chronic gout refractory / Deficiency / constipation / pruritus / rash / methemoglobinemia / wheezing / /MedicalTreatmentintravenous infusion / /OrganizationBefore administration / DOSAGE AND ADMINISTRATION / FDA / / /PositionGeneral Information 17.2 Anaphylaxis / physician / /Productacetaminophen / Sodium Chloride / KRYSTEXXA / /RegionMediterranean / /TechnologyPharmacokinetics / mPEG / antibodies / microwave / Pharmacodynamics / /URLwww.fda.gov/medwatch / /SocialTag |